Dronedarone: an amiodarone analogue

决奈达隆 胺碘酮 医学 心房颤动 心脏病学 内科学 抗心律失常药 药理学 窦性心律 心脏复律 麻醉 心脏病
作者
Sheila A Doggrell,Jules C. Hancox
出处
期刊:Expert Opinion on Investigational Drugs [Informa]
卷期号:13 (4): 415-426 被引量:48
标识
DOI:10.1517/13543784.13.4.415
摘要

Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardiac side effects and this has driven development of amiodarone analogues. These analogues include short acting analogues (e.g., AT-2001) with similar acute effects to amiodarone, the thyroid receptor antagonist KB-130015 and dronedarone. Dronedarone, (SR-33589; Sanofi-Synthelabo), is a non-iodinated amiodarone derivative that inhibits Na+, K+ and Ca2+ currents. It is a potent inhibitor of the acetylcholine-activated K+ current from atrial and sinoatrial nodal tissue, and inhibits the rapid delayed rectifier more potently than slow and inward rectifier K+ currents and inhibits L-type calcium current. Dronedarone is an antagonist at α- and β-adrenoceptors and unlike amiodarone, has little effect at thyroid receptors. Dronedarone is more potent than amiodarone in inhibiting arrhythmias and death in animal models of ischaemia- and reperfusion-induced arrhythmias. In the Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) clinical trial, dronedarone 800 mg/day appeared to be effective and safe for the prevention of atrial fibrillation relapses after cardioversion. The Antiarrhythmic Trial with Dronedarone in Moderate-to-Severe Congestive Heart Failure Evaluating Morbidity Decrease (ANDROMEDA) trial was stopped due to a potential increased risk of death in the dronedarone group. Trials of dronedarone in the maintenance of sinus rhythm in patients with atrial fibrillation and a safety and tolerability study in patients with an implantable cardioverter defibrillator are ongoing. Further experimental and clinical studies are required before we have a definitive answer to whether dronedarone has advantages over amiodarone and other amiodarone analogues.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助Halo采纳,获得10
4秒前
彭于晏应助万刈采纳,获得10
6秒前
6秒前
GXY完成签到,获得积分10
10秒前
11秒前
科研小白发布了新的文献求助10
11秒前
曲终人散完成签到,获得积分10
13秒前
cd完成签到,获得积分10
14秒前
科研通AI2S应助XUST胖谢采纳,获得10
15秒前
15秒前
大个应助酷炫夏山采纳,获得10
16秒前
16秒前
lalala发布了新的文献求助10
17秒前
Ellen完成签到 ,获得积分10
18秒前
脑洞疼应助科研小白采纳,获得10
19秒前
可爱的函函应助Caffery采纳,获得10
20秒前
xiaodu20230228完成签到 ,获得积分10
21秒前
22秒前
鲤鱼完成签到,获得积分10
22秒前
离言完成签到,获得积分10
22秒前
科目三应助南风不竞采纳,获得10
22秒前
传奇3应助科研通管家采纳,获得10
23秒前
田様应助科研通管家采纳,获得10
23秒前
所所应助科研通管家采纳,获得10
23秒前
CipherSage应助科研通管家采纳,获得10
23秒前
慕青应助科研通管家采纳,获得10
23秒前
小二郎应助科研通管家采纳,获得10
23秒前
23秒前
GGGGD完成签到,获得积分10
29秒前
有魅力棉花糖完成签到,获得积分10
29秒前
脑洞疼应助Gravity采纳,获得50
30秒前
充电宝应助小雒雒采纳,获得10
30秒前
31秒前
32秒前
mirror完成签到,获得积分10
34秒前
34秒前
SciGPT应助黄毛虎采纳,获得10
34秒前
35秒前
庞扬完成签到,获得积分20
37秒前
削菠萝发布了新的文献求助10
37秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Saponins and sapogenins. IX. Saponins and sapogenins of Luffa aegyptica mill seeds (black variety) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3259819
求助须知:如何正确求助?哪些是违规求助? 2901303
关于积分的说明 8314986
捐赠科研通 2570798
什么是DOI,文献DOI怎么找? 1396675
科研通“疑难数据库(出版商)”最低求助积分说明 653554
邀请新用户注册赠送积分活动 631853